Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
This study is currently enrolling.
This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug th ...